bioAffinity Technologies Secures $4 Million in Direct Offering

The Texas-based biotechnology firm set the purchase price at $6.122 per share of common stock, with pre-funded warrants priced at $6.115. As part of the concurrent private placement, investors will receive warrants to purchase up to 980,072 shares, exercisable at $6.122 following mandatory stockholder approval. These warrants carry a five-year term.

Management plans to allocate the net proceeds toward general corporate purposes and working capital, specifically targeting the expansion of sales for CyPath Lung, the company’s noninvasive test for early lung disease detection. The transaction is expected to close on or about October 9, 2026, provided that customary closing conditions are met. Securities are being issued under a previously effective shelf registration statement filed with the U.S. Securities and Exchange Commission.